I
ncreased utilization of vena cava filters (VCFs) for venous thromboembolism (VTE) has correlated with technical improvements in the placement of VCFs and development of retrievable devices. 1 By 2006, roughly 9% of cases of deep vein thrombosis (DVT) and 12% of pulmonary embolism (PE) received a VCF and has continued to increase into 2012 with an estimated 259,000 VCFs placed in patients in the United States. 2, 3 This increase persists despite mixed recommendations and an overall lack of evidence for the use of VCFs. [4] [5] [6] [7] Given the potential for suboptimal use and wide variation between hospitals, 8 it is important to understand hospital-level and patient-level factors associated with utilization. Identifying these factors will assist in assessing the quality of care for patients presenting with DVT/PE and can also indicate subpopulations that may be of interest for future research. Thus, this study sought to characterize patients with VTE who received VCFs and to observe the amount of variation between hospitals.
METHODS

Data Source
State Inpatient Database data from Kentucky were used from 2008 to 2014. Data include patient demographic variables (age, sex, race, insurance, and ZIP codes) and diagnosis and procedure fields. Data are deidentified and do not include unique patient identifiers, so no longitudinal tracking is possible. The University of Kentucky Institutional Review Board approved the study.
Study Variables
The coding algorithms used are presented in the Appendix (Supplemental Digital Content 1, http://links.lww. com/MLR/B242) and are based on previously published coding algorithms. [8] [9] [10] [11] [12] All diagnoses for DVT (451.xx, 453.xx) and PE (415.1x) were identified for those aged 21 and older from acute care hospitals. VCF use was identified by ICD-9-CM procedure code 38.7. Discharges from hospitals where no VCFs were placed over the entire 7-year period were excluded to avoid bias due to hospitals lacking the ability to perform the procedure. Variation in VCF use was described by the mean, median, interquartile range, and coefficient of variation.
Patients were classified as having DVT only, PE only, or having PE+DVT. Comorbidities identified included cancer, chronic obstructive pulmonary disease, cerebrovascular disease (CVD), atrial fibrillation (AFib), liver disease, hypertension, heart failure, hyperlipidemia, myocardial infarction, cellulitis, trauma, diabetes, infection, pneumonia, renal disease, bleeding, anemia, and sepsis/septic shock. 12, 13 In addition, thrombolytic therapy and embolectomy/thrombectomy procedures were identified. Unstable patients were identified as those with shock or ventilator use. Invasive surgical procedures were identified using a validated algorithm. 14 Discharge statuses of "deceased" or "transferred" were also recorded. Age was categorized by a 5-year interval, race was categorized white, black, or other, and insurance classified as commercial, Medicaid, Medicare, or other/self-pay. Individual hospitals were classified as being urban or rural, teaching or nonteaching, and categorized into quartiles by hospital bed size.
Statistical Analysis
Comparisons were conducted between demographic and clinical characteristics using t tests and w 2 tests where appropriate using an a priori, 2-sided significance level of 0.05. P-values are reported for comparisons between VCF users and nonusers. Hierarchical generalized linear modeling was used (henceforth: hierarchical logistic models) for the binary outcome of VCF use. 15 These models included random effects for each hospital and fixed effects for other covariates. 15, 16 A cancer-only model was also estimated in the cancer subgroup with additional variables for cancer site (Table 4) . Odds ratios (ORs) and their 95% confidence intervals are presented for each variable from the final, full model. The intraclass correlation coefficient (ICC) was calculated for each model, which measures the variation explained by the hospital random effects. The P-value associated with the ICC corresponds to the comparison of between-hospital variance with P < 0.05 showing significant differences. In addition, c-statistics were calculated as a measure of model discriminatory power between VCF users and nonusers. Akaike and Bayesian information criteria were included to compare across models, which measure the fit of the models while penalizing for added parameters. All analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC).
RESULTS
A total of 70 acute care hospitals were included in the state. Eleven hospitals placed no VCFs and were excluded (N = 2435 patients, 2.9% of total discharges). Among the remaining institutions (N = 59), VCF use ranged from 0.4% to 15.2%, mean 7.2%, median 7.2%, interquartile range 4.1% to 10.1%, and coefficient of variation of 0.54. There were 81,922 VTE-related hospital discharges and 10.5% of patients (N = 7786) received a VCF. The VCF group tended to have an older age distribution, more PE+DVT, cancer, CVD, AFib, anemia, and trauma compared with those without VCFs ( Table 1 ). The VCF group was also more likely to be unstable, have proximal and lower DVTs, have bleeding, and receive thrombolysis.
The random effects-only model resulted in an ICC of 12.0% (P < 0.001) and c-statistic of 0.62, showing that there was a significant difference between hospitals, which explained 12% of the overall variance in use ( Table 2 ). The full model had an ICC of 7.1% (P < 0.001) and c-statistic of 0.81. The cancer-only model had an ICC of 3.5% (P < 0.001) and c-statistic of 0.81.
The results of the full model (Table 3) showed that beginning at 46-50 years of age, the odds of receiving a VCF increased compared with the reference group (21-25 y old). This trend continued with those over the age 65 being twice as likely to receive a VCF. Compared with patients with DVT only, those with PE only [OR = 3.84 (3.46-4.25)] and PE+DVT [OR = 2.73 (2.57-2.90)] were much more likely to receive VCFs. Among DVTs, those with lower DVTs were >6-fold more likely to receive a VCF compared with upper extremity DVTs. Those with bleeding, cancer, liver disease, anemia, and AFib were also more likely to receive VCFs (Table 3) .
Among those with cancer (N = 13,104), 1613 (12.3%) used VCFs. The most common cancers were lung (N = 3931, 30.0% of all cancers) and colorectal cancer (N = 1392, 10.6%). Of the 22 cancer sites identified, all but 5 had higher utilization of VCFs than in the average cohort ( 
DISCUSSION
The primary findings suggest that while there is a wide variation in VCF utilization between institutions, most of that variation is controlled for by patient and hospital characteristics. In the final model, very little variation (B7%) in VCF use was attributed to hospitals. Among comorbid conditions considered, our results show strong associations with VCF use and cancer, CVD, AFib, anemia, and concurrent bleeding. This shows that consideration of baseline risk of thromboembolic and bleeding events is considered at the point of care. However, competing guideline statements make it difficult to assess the appropriateness of VCF use in subgroups at a high risk of VTE, but not necessarily contraindicated to anticoagulation. 4, 5, 7 In this study, 20% of patients with bleeding received a VCF, a subgroup that is most likely truly contraindicated to coagulation, and were 2.7 times more likely to receive a filter in adjusted analyses. VCF use was also associated with characteristics that indicate severity including unstable patients, surgery, receipt of thrombolysis or embolectomy procedures, and trauma.
The association between cancer and VCF use prompted a more detailed look into individual cancers. Patients with cancer are at an exceedingly high risk of VTE compared with the general population. 17 Further, given the complexity of regimens, multiple drug-drug or drug-disease interactions, and side effects of cancer treatments and many surgical procedures, systemic anticoagulation may be considered infeasible for many cancer patients. 18 However, prior studies have shown that anticoagulants are often used in addition to VCFs. 3, 19 In this study, VCF use was highest for brain cancers, likely due to the high risk of intracranial bleeding.
The evidence for VCFs for PE/DVT is mixed, making conclusive arguments for use difficult. In the PREPIC 20, 21 and PREPIC-2 22 randomized trials, no significant benefits were observed with VCFs with anticoagulation versus anticoagulation alone during short-term and long-term followup. Observational studies show that VCFs are associated with improvements in short-term outcomes such as in-hospital mortality, 30-day mortality, and a reduction in subsequent PE events among all VTE patients and certain subgroups (trauma, unstable, and elderly). [23] [24] [25] [26] Other studies have shown little or no benefit with VCFs, especially with longer follow-up. 9, 19, 27, 28 Retrievable filters have become widely used in the last decade. Sarosiek et al 3 evaluated the use of retrievable filters and subsequent complications at a single academic center. Their main findings showed there was attempted retrieval in only 10% of VCFs. Of those retrieved, one-quarter were removed during the index hospitalization and the median time-to-retrieval was observed to be 122 days after placement. Their study further emphasized the lack of follow-up for patients receiving a VCF and a number of serious complications including filter fracture and migration. The authors emphasized the need for follow-up and proper retrieval of devices to avoid complications associated with VCFs. This has been observed in other studies, as well, showing that utilization and retrieval rates as potential quality of care issues and deserve dedicated interventions to ensure quality outcomes for patients. [29] [30] [31] Although our results suggest no institutional deviance in VCF use, there may still exist a general overuse of these devices, which is not definitively supported by current evidence and is further confounded given the lack of consensus in treatment guidelines. There is a great need for additional research in the effectiveness of VCFs in real-world practice, especially for subgroups at highest risk of complications.
Limitations
Because of the nature of the data, temporality of VCF placement and VTE cannot be assessed. It is probable that some patients receive VCF before experiencing a VTE, which is important for patients who may have received VCFs for prophylaxis, most likely subgroups at higher risk of VTE. Data that allow for temporal assessment of VCF placement and VTE will help in understanding the significance of this limitation. Detailed information on medication utilization or the type of VCF placed (retrievable/permanent, manufacturer) is also not possible with discharge data. This is important to distinguish those who would and would not use anticoagulants in place of, or concurrently with, VCFs as these groups may differ in clinical presentation and treatment course. Previous studies have shown that anticoagulants are often used with VCFs, likely proving that use persists without clear contraindications to anticoagulation therapy. 3 A broader definition of DVT was used than what has been used in other studies as well as extending the diagnosis position for VTE disorders beyond only the primary position. This was done to catch more thrombotic disorders where VCFs may be used. Use of these additional codes contributed 14% of the total VTEs with no difference in the prevalence of VCF utilization for these codes compared with more common codes and patient characteristics were similarly distributed. The data include no unique patient-identifying variable; it is possible that multiple records for the same individual are included in the analyses. This would be due to multiple hospitalizations over the time period, including patients who transfer from one facility to another. To investigate the impact of transfers, we included an indicator for whether a patient transferred or not, as this may also indicate severity and influence whether a patient receives a VCF from that institution. Similarly, longitudinal tracking of patients is not possible; thus, short-term or long-term outcomes cannot be assessed using State Inpatient Database data. At both a patient-level and institutional-level, transfer status and transfer rate were not significantly associated with VCF utilization. Finally, the data represent the patient population and medical practice within Kentucky and may have limited generalizability to other areas due to differences in comorbid conditions and practices between regions.
CONCLUSIONS
In this study of VCF use in Kentucky, we found that much of the between-hospital variation is explained by observed hospital and patient characteristics and little variation existed between hospitals after controlling for these factors. More research is needed to assess the effectiveness of VCFs, especially in high-risk subgroups such as cancer, elderly, high-bleed risk, and trauma patients.
